Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# Valeo Pharma

Healthcare Innovations for Canadians

## Sitemaps

- [XML Sitemap](https://valeopharma.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [VALEO PHARMA ANNONCE DE NOUVELLES NOMINATIONS AU CONSEIL D'ADMINISTRATION](https://valeopharma.com/valeo-pharma-annonce-de-nouvelles-nominations-au-conseil-dadministration/) - MONTRÉAL (QUÉBEC), le 22 juin 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd'hui que Mme Tamara Close et M. Didier Leconte se sont joints à son Conseil d'administration. Suite à la nomination de Mme Close et de M. Leconte, le
- [VALEO PHARMA ANNOUNCES NEW BOARD APPOINTMENTS](https://valeopharma.com/valeo-pharma-announces-new-board-appointments/) - MONTREAL, QUEBEC, June 22, 2023 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that Ms. Tamara Close and Mr. Didier Leconte have joined its Board of Directors. Following the appointment of Ms. Close and Mr. Leconte, Valeo’s Board of Directors is now comprised
- [VALEO PHARMA ANNONCE DES REVENUS RECORDS POUR LE DEUXIÈME TRIMESTRE](https://valeopharma.com/valeo-pharma-annonce-des-revenus-records-pour-le-deuxieme-trimestre/) - Sixième trimestre consécutif de croissance des revenus à 13,6 millions $ au T2-2023, en hausse de 184% par rapport au T2-2022 Sixième trimestre consécutif de réduction de la perte du BAIIA ajusté à 1,7 million $, soit une amélioration de 53 % par rapport au T2-2022, et une baisse de 24 % par rapport au
- [VALEO PHARMA REPORTS RECORD SECOND QUARTER REVENUES](https://valeopharma.com/valeo-pharma-reports-record-second-quarter-revenues/) - Sixth consecutive quarter of revenue growth at $13.6 million in Q2-23, up 184% over Q2-22. Sixth consecutive quarter of adjusted EBITDA loss reduction at $1.7 million, a 53% improvement over Q2-22, and down 24% compared to Q1-23 Physicians prescribing Enerzair and Atectura reached 2,036 at the end of Q2-23, representing 29% growth from the prior
- [VALEO PHARMA ANNONCE UN CHIFFRE D'AFFAIRES ANNUEL RECORD POUR L'EXERCICE 2023](https://valeopharma.com/valeo-pharma-annonce-un-chiffre-daffaires-annuel-record-pour-lexercice-2023/) - Revenus records de 54 millions $ pour l’exercice 2023, en hausse de 94 % comparativement à 2022 Revenus de 13,1 millions $ pour le T4-23, en hausse de 4 % comparativement au T4-22 Bénéfice brut ajusté annuel record de 16,9 millions $ pour 2023, contre 9,4 millions $ pour 2022, en hausse de 80% Perte
- [VALEO PHARMA REPORTS RECORD ANNUAL REVENUES FOR FISCAL YEAR 2023](https://valeopharma.com/valeo-pharma-reports-record-annual-revenues-for-fiscal-year-2023/) - Record revenues of $54 million for fiscal 2023, up 94% over 2022 Revenues of $13.1 million for Q4-23, up 4% over Q4-22 Record annual adjusted gross profit of $16.9 million for 2023, compared to $9.4 million for 2022, up 80% 2023 adjusted EBITDA loss of $10.9 million compared to $14.5 million for 2022, down 25%
- [VALEO PHARMA TIENDRA UNE CONFÉRENCE TÉLÉPHONIQUE / WEBDIFFUSION POUR SES RÉSULTATS DU QUATRIÈME TRIMESTRE ET DE L’ANNÉE 2023](https://valeopharma.com/valeo-pharma-tiendra-une-conference-telephonique-webdiffusion-pour-ses-resultats-du-quatrieme-trimestre-et-de-lannee-2023/) - MONTRÉAL (QUÉBEC), le 22 janvier 2024 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd'hui qu'elle divulguera ses résultats financiers et faits saillants pour le quatrième trimestre et l’exercice financier clos le 31 octobre 2023 le lundi 29 janvier 2024 après la
- [VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2023 RESULTS CONFERENCE CALL / WEBCAST     ](https://valeopharma.com/valeo-pharma-to-host-fourth-quarter-and-year-end-2023-results-conference-call-webcast/) - MONTREAL, QUEBEC , January 22, 2024 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended October 31, 2023 on Monday January 29, 2024 after market close. The Company will host
- [VALEO PHARMA ANNONCE  DES CHANGEMENTS ORGANISATIONNELS ET DES INITIATIVES DE RÉDUCTION DES COÛTS](https://valeopharma.com/valeo-pharma-annonce-des-changements-organisationnels-et-des-initiatives-de-reduction-des-couts/) - Les initiatives de réduction des coûts et le réalignement organisationnel devraient générer des économies annuelles de plus de 2 millions $. MONTRÉAL (QUÉBEC), le 20 novembre 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd'hui qu'elle a entrepris une série d'initiatives
- [VALEO PHARMA ANNOUNCES ORGANIZATIONAL CHANGES AND COST REDUCTION INITIATIVES](https://valeopharma.com/valeo-pharma-announces-organizational-changes-and-cost-reduction-initiatives/) - Costs reduction initiatives and organizational realignment expected to generate annual savings exceeding $2 million. MONTREAL, QUEBEC, November 20, 2023 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that it has undertaken a series of initiatives to reduce operating costs and drive operational efficiency
- [VALEO PHARMA ANNONCE LA NOMINATION DE M. RICHARD LAJOIE À SON CONSEIL D’ADMINISTRATION](https://valeopharma.com/valeo-pharma-annonce-la-nomination-de-m-richard-lajoie-a-son-conseil-dadministration/) - MONTRÉAL (QUÉBEC), le 7 novembre 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd'hui que M. Richard Lajoie s'est joint au conseil d'administration de la Société et que Mme Maureen C. Brennan s'est retirée de son conseil d'administration. « Nous sommes
- [VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. RICHARD LAJOIE TO BOARD OF DIRECTORS](https://valeopharma.com/valeo-pharma-announces-appointment-of-mr-richard-lajoie-to-board-of-directors/) - MONTREAL, QUEBEC, November 7, 2023 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that Mr. Richard Lajoie has joined the Company's Board of Directors and that Ms. Maureen C. Brennan has retired from its Board of Directors “We are pleased to welcome Richard
- [VALEO PHARMA FIGURE SUR LA LISTE DU CINQUIÈME CLASSEMENT ANNUEL DES ENTREPRISES CANADIENNES EN PLUS FORTE CROISSANCE DU GLOBE AND MAIL](https://valeopharma.com/valeo-pharma-figure-sur-la-liste-du-cinquieme-classement-annuel-des-entreprises-canadiennes-en-plus-forte-croissance-du-globe-and-mail/) - MONTRÉAL (QUÉBEC), le 4 octobre 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, est heureuse d'annoncer qu'elle s'est classée au 151e rang du palmarès 2023 du Report on Business des sociétés canadiennes affichant la plus forte croissance. Le palmarès des entreprises en plus
- [VALEO PHARMA MAKES THE LIST OF THE GLOBE AND MAIL’S FIFTH-ANNUAL RANKING OF CANADA’S TOP GROWING COMPANIES     ](https://valeopharma.com/valeo-pharma-makes-the-list-of-the-globe-and-mails-fifth-annual-ranking-of-canadas-top-growing-companies/) - MONTREAL, QUEBEC , October 4, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, is pleased to announce it placed No. 151 on the 2023 Report on Business ranking of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Valeo placed
- [VALEO PHARMA CONCLUT UNE ENTENTE DE FACILITÉ DE CRÉDIT DE 5 MILLIONS $ AVEC ACCORD FINANCIAL INC.](https://valeopharma.com/valeo-pharma-conclut-une-entente-de-facilite-de-credit-de-5-millions-avec-accord-financial-inc/) - MONTRÉAL (QUÉBEC), le 27 septembre 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne a annoncé aujourd'hui qu'elle avait conclu une entente de facilité de crédit avec Financière Accord inc. La facilité de crédit de 5 millions $ est garantie par un privilège de
- [VALEO PHARMA ENTERS INTO $5 MILLION CREDIT FACILITY AGREEMENT WITH ACCORD FINANCIAL INC.     ](https://valeopharma.com/valeo-pharma-enters-into-5-million-credit-facility-agreement-with-accord-financial-inc/) - MONTREAL, QUEBEC , September 27, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it has entered into a credit facility agreement with Accord Financial Inc. The $5 million credit facility is secured by a first rank lien on the Corporation’s short term assets,
- [VALEO PHARMA ANNONCE DES REVENUS RECORDS POUR LE TROISIÈME TRIMESTRE DE 2023](https://valeopharma.com/valeo-pharma-annonce-des-revenus-records-pour-le-troisieme-trimestre-de-2023/) - Septième trimestre consécutif de croissance des revenus à 14.1 millions $ au T3-2023, en hausse de 132% par rapport au T3-2022 Le nombre de médecins prescrivant Enerzair et Atectura a atteint 2 503 à la fin du T3-2023, soit une croissance de 23 % par rapport au trimestre précédent et de 221 % comparativement à
- [VALEO PHARMA REPORTS RECORD THIRD QUARTER 2023 REVENUES](https://valeopharma.com/valeo-pharma-reports-record-third-quarter-2023-revenues/) - Seventh consecutive quarter of revenue growth at $14.1 million in Q3-23, up 132% over Q3-22. Physicians prescribing Enerzair and Atectura reached 2,503 at the end of Q3-23, representing a 23% increase from the prior quarter and a 221% rise year-over-year Total Enerzair and Atectura prescriptions for the 12 months ending July 31, 2023 exceeded 56,000,
- [VALEO PHARMA TIENDRA UNE CONFÉRENCE TÉLÉPHONIQUE / WEBDIFFUSION POUR SES RÉSULTATS DU TROISIÈME TRIMESTRE DE 2023](https://valeopharma.com/valeo-pharma-tiendra-une-conference-telephonique-webdiffusion-pour-ses-resultats-du-troisieme-trimestre-de-2023/) - MONTRÉAL (QUÉBEC), le 7 septembre 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd'hui qu'elle divulguera ses résultats financiers et faits saillants pour le troisième trimestre clos le 31 juillet 2023 le mercredi 13 septembre 2023 après la fermeture des marchés.
- [VALEO PHARMA TO HOST THIRD QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST     ](https://valeopharma.com/valeo-pharma-to-host-third-quarter-2023-results-conference-call-webcast/) - MONTREAL, QUEBEC , September 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2023 on Wednesday September 13, 2023 after market close. The Company will host a conference
- [VALEO PHARMA CONCLUT UN FINANCEMENT DE 4,5 MILLIONS $](https://valeopharma.com/valeo-pharma-conclut-un-financement-de-45-millions/) - 3,92 millions $ provenant d'un placement privé sans intermédiaire, et 0,58 million $ provenant d'un prêt d'un initié Investissement Québec et les initiés investissent chacun 2,0 millions $ Les produits du financement serviront à renforcer le fonds de roulement et soutenir la croissance continue MONTRÉAL (QUÉBEC), le 31 août 2023 – Valeo Pharma inc. (TSX :
- [VALEO PHARMA CLOSES $4.5 MILLION FINANCING](https://valeopharma.com/valeo-pharma-closes-4-5-million-financing/) - $3.92 million raised from non-brokered private placement offering, and $0.58 million from insider loan Investissement Québec and insiders each invest $2.0 million Proceeds from the financing to be used to strengthen working capital and support ongoing growth MONTREAL, QUEBEC, August 31, 2023 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”),
- [VALEO PHARMA FAIT LE POINT SUR SON UNITÉ D'AFFAIRES D’OPHTALMOLOGIE](https://valeopharma.com/valeo-pharma-fait-le-point-sur-son-unite-daffaires-dophtalmologie/) - Novartis accepte de vendre à Bausch + Lomb les droits mondiaux de XIIDRA® et de plusieurs autres produits ophtalmologiques SIMBRINZA® n'est pas inclus dans la cession MONTRÉAL (QUÉBEC), le 4 juillet 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, prend acte du communiqué
- [VALEO PHARMA PROVIDES UPDATE ON OPHTHALMOLOGY BUSINESS UNIT](https://valeopharma.com/valeo-pharma-provides-update-on-ophthalmology-business-unit/) - Novartis agrees to sell global rights to XIIDRA® and several other ophthalmology products to Bausch + Lomb SIMBRINZA® not included in the divestiture MONTREAL, QUEBEC, July 4, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, notes from the news release issued by Novartis on June 30, 2023
- [VALEO PHARMA TIENDRA UNE CONFÉRENCE TÉLÉPHONIQUE / WEBDIFFUSION POUR SES RÉSULTATS DU SECOND TRIMESTRE DE 2023](https://valeopharma.com/valeo-pharma-tiendra-une-conference-telephonique-webdiffusion-pour-ses-resultats-du-second-trimestre-de-2023/) - MONTRÉAL (QUÉBEC), le 7 juin 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd'hui qu'elle divulguera ses résultats financiers et faits saillants pour le second trimestre clos le 30 avril 2023 le mardi 13 juin 2023 après la fermeture des marchés.
- [VALEO PHARMA TO HOST SECOND QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST     ](https://valeopharma.com/valeo-pharma-to-host-second-quarter-2023-results-conference-call-webcast/) - MONTREAL, QUEBEC , June 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2023 on Tuesday June 13, 2023 after market close. The Company will host a conference
- [VALEO PHARMA ANTICIPE DES REVENUS RECORDS POUR LE DEUXIÈME TRIMESTRE DE 2023 ](https://valeopharma.com/valeo-pharma-anticipe-des-revenus-records-pour-le-deuxieme-trimestre-de-2023/) - Les revenus du T2-23 devraient dépasser 13,5 millions $ La perte de BAIIA ajusté du T2-23 devrait être inférieure à 2,0 millions $ Les dépenses d'exploitation du T2-23 resteront conformes à celles des trimestres précédents Les revenus trimestriels d'ENERZAIR® et d'ATECTURA® augmentent de 270 % par rapport à l'année précédente MONTRÉAL (QUÉBEC), le 25 mai
- [VALEO PHARMA PROVIDING GUIDANCE OF RECORD REVENUES FOR THE SECOND QUARTER 2023 ](https://valeopharma.com/valeo-pharma-providing-guidance-of-record-revenues-for-the-second-quarter-2023/) - Q2-23 revenues to exceed $13.5 million Q2-23 adjusted EBITDA loss to decrease below $2.0 million Q2-23 operating expenses to remain in line with prior quarters ENERZAIR® and ATECTURA® quarterly revenues grow 270% over prior year MONTREAL, QUEBEC , May 25, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian
- [<strong>VALEO PHARMA ANNONCE LES RÉSULTATS DE L'ASSEMBLÉE ANNUELLE DES ACTIONNAIRES ET LES NOMINATIONS AUX COMITÉS</strong>](https://valeopharma.com/valeo-pharma-annonce-les-resultats-de-lassemblee-annuelle-des-actionnaires-et-les-nominations-aux-comites/) - MONTRÉAL (QUÉBEC), le 28 avril 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd'hui les résultats des propositions soumises aux actionnaires lors de son assemblée annuelle des actionnaires tenue le 27 avril 2023 (« l’Assemblée »). Élection des administrateurs Les résultats du vote
- [<strong>VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS AND COMMITTEE APPOINTMENTS</strong>](https://valeopharma.com/valeo-pharma-announces-results-of-annual-meeting-of-shareholders-and-committee-appointments/) - MONTREAL, QUEBEC , April 28, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced the results of the proposals submitted to shareholders at its annual meeting of shareholders held on April 27, 2023 (the “Meeting”). Election of Directors The results of the vote for those
- [<strong>VALEO PHARMA PRÉSENTERA À LA CONFÉRENCE POUR INVESTISSEURS 2023 DE BLOOM BURTON & CO  </strong>](https://valeopharma.com/valeo-pharma-presentera-a-la-conference-pour-investisseurs-2023-de-bloom-burton-co/) - MONTRÉAL (QUÉBEC), le 19 avril 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd'hui que Steve Saviuk, Chef de la Direction de Valeo, présentera un survol corporatif de l'entreprise et fournira une mise à jour commerciale sur les principaux produits de
- [<strong>VALEO PHARMA TO PRESENT AT THE 2023 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE  </strong>](https://valeopharma.com/valeo-pharma-to-present-at-the-2023-bloom-burton-co-healthcare-investor-conference/) - MONTREAL, QUEBEC , April 19, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that Steve Saviuk, Valeo’s Chief Executive Officer, will present a corporate overview and provide a commercial update on key products of the Company at the 2023 Bloom Burton & Co Healthcare
- [<strong>VALEO PHARMA ANNONCE DES REVENUS TRIMESTRIELS RECORDS POUR LE PREMIER TRIMESTRE DE 2023</strong>](https://valeopharma.com/valeo-pharma-annonce-des-revenus-trimestriels-records-pour-le-premier-trimestre-de-2023/) - • Cinquième trimestre consécutif de croissance des revenus à 13,2 millions $ au premier trimestre de 2023, en hausse de 210 % comparativement au premier trimestre de 2022 • Cinquième trimestre consécutif d’augmentation du bénéfice brut ajusté à 4,2 millions $, en hausse de 178 % comparativement au premier trimestre de 2022 • Cinquième trimestre
- [<strong>VALEO PHARMA REPORTS RECORD QUARTERLY REVENUES FOR THE FIRST QUARTER 2023</strong>](https://valeopharma.com/valeo-pharma-reports-record-quarterly-revenues-for-the-first-quarter-2023/) - • Fifth consecutive quarter of revenue growth at $13.2 million in Q1-23, up 210% over Q1-22 • Fifth consecutive quarter of adjusted gross profit increase at $4.2 million, up 178% over Q1-22 • Fifth consecutive quarter of adjusted EBITDA loss reduction at $2.2 million, a 51% improvement over Q1-22 • Physicians prescribing Enerzair and Atectura
- [<strong>VALEO PHARMA TIENDRA UNE CONFÉRENCE TÉLÉPHONIQUE / WEBDIFFUSION POUR SES RÉSULTATS DU PREMIER TRIMESTRE DE 2023</strong>](https://valeopharma.com/valeo-pharma-tiendra-une-conference-telephonique-webdiffusion-pour-ses-resultats-du-premier-trimestre-de-2023/) - MONTRÉAL (QUÉBEC), le 9 mars 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd'hui qu'elle divulguera ses résultats financiers et faits saillants pour le premier trimestre clos le 31 janvier 2023 le mercredi 15 mars 2023 après la fermeture des marchés.
- [<strong>VALEO PHARMA TO HOST FIRST QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST     </strong>](https://valeopharma.com/valeo-pharma-to-host-first-quarter-2023-results-conference-call-webcast/) - MONTREAL, QUEBEC , March 9, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2023 on Wednesday March 15, 2023 after market close. The Company will host a conference
- [<strong>VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ONSTRYV® IN QUEBEC</strong>](https://valeopharma.com/valeo-pharma-obtains-public-reimbursement-for-onstryv-in-quebec/) - Quebec public reimbursement coverage to facilitate and expand medication access for Parkinson’s patients in Quebec MONTREAL, QUEBEC , February 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that Onstryv® (safinamide) for the treatment of patients suffering from Parkinson’s disease, is now listed
- [VALEO PHARMA OBTIENT LE REMBOURSEMENT PUBLIC D’ONSTRYV AU QUÉBEC](https://valeopharma.com/valeo-pharma-obtient-le-remboursement-public-donstryv-au-quebec/) - La couverture de remboursement public au Québec facilitera et élargira l'accès aux médicaments pour les patients atteints de la maladie de Parkinson au Québec MONTRÉAL (QUÉBEC), le 7 février 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo »), une société pharmaceutique canadienne, a annoncé aujourd'hui qu'Onstryv (safinamide) pour
- [VALEO PHARMA ANNONCE DES REVENUS TRIMESTRIELS ET ANNUELS RECORDS POUR LE QUATRIÈME TRIMESTRE ET L’ANNÉE FINANCIÈRE 2022](https://valeopharma.com/valeo-pharma-annonce-des-revenus-trimestriels-et-annuels-records-pour-le-quatrieme-trimestre-et-lannee-financiere-2022/) - Revenus trimestriels records de 12,7 millions $ en T4 2022, en hausse de 274 % comparativement au quatrième trimestre de 2021 Revenus records de 27,7 millions $ en 2022, en hausse de 105 % comparativement à 2021 Revenus records prévus pour le premier trimestre de 2023 Création de l'unité d’affaires ophtalmologie suite à l'ajout de
- [<strong>VALEO PHARMA REPORTS RECORD QUARTERLY AND ANNUAL REVENUES FOR THE FOURTH QUARTER AND THE FISCAL YEAR 2022 </strong>](https://valeopharma.com/valeo-pharma-reports-record-quarterly-and-annual-revenues-for-the-fourth-quarter-and-the-fiscal-year-2022/) - Record quarterly revenues of $12.7 million in Q4-22, up 274% over Q4-21 Record revenues in 2022 of $27.7 million, up 105% over 2021 Record revenues forecasted in Q1-23 Creation of Ophthalmology Business Unit following the addition of XIIDRA® and SIMBRINZA®, expansion of Respiratory Business Unit to include allergy following the addition of ALLERJECT® In excess
- [<strong>VALEO PHARMA ANNONCE LE DÉPÔT D’UNE PRÉSENTATION DE</strong> <strong>DROGUE NOUVELLE-COVID 19 AUPRÈS DE SANTÉ CANADA POUR SABIZABULIN POUR </strong> <strong>LE TRAITEMENT DES PATIENTS HOSPITALISÉS ATTEINTS DE COVID-19</strong>](https://valeopharma.com/valeo-pharma-annonce-le-depot-dune-presentation-de-drogue-nouvelle-covid-19-aupres-de-sante-canada-pour-sabizabulin-pour-le-traitement-des-patients-hospitalises-atteints-de-covid-19/) - Lors de l'analyse finale de l'étude clinique de phase 3 menée par Veru Inc, sabizabulin a démontré une réduction de 51,6 % des décès comparativement au placebo chez les patients adultes hospitalisés atteints de COVID-19 modéré à sévère et présentant un risque élevé de SDRA Sabizabulin a également démontré une réduction significative du nombre de
- [<strong>VALEO PHARMA ANNOUNCES FILING OF A NEW DRUG SUBMISSION-COVID 19 WITH HEALTH CANADA FOR SABIZABULIN FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS</strong>](https://valeopharma.com/valeo-pharma-announces-filing-of-a-new-drug-submission-covid-19-with-health-canada-for-sabizabulin-for-the-treatment-of-hospitalized-covid-19-patients/) - In the final analysis of the Phase 3 cinical study conducted by Veru Inc., sabizabulin showed a 51.6% reduction in deaths compared to placebo in hospitalized adult patients with moderate to severe COVID-19 who are at high risk for ARDS Sabizabulin also showed a significant reduction of days in ICU, days on mechanical ventilation and
- [<strong>VALEO PHARMA TIENDRA UNE CONFÉRENCE TÉLÉPHONIQUE / WEBDIFFUSION POUR SES RÉSULTATS DU QUATRIÈME TRIMESTRE ET DE L’ANNÉE 2022</strong>](https://valeopharma.com/valeo-pharma-tiendra-une-conference-telephonique-webdiffusion-pour-ses-resultats-du-quatrieme-trimestre-et-de-lannee-2022/) - MONTRÉAL (QUÉBEC), le 25 janvier 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd'hui qu'elle divulguera ses résultats financiers et faits saillants pour le quatrième trimestre et exercice financier clos le 31 octobre 2022 le lundi 30 janvier 2023 après la
- [<strong>VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2022 RESULTS CONFERENCE CALL / WEBCAST     </strong>](https://valeopharma.com/valeo-pharma-to-host-fourth-quarter-and-year-end-2022-results-conference-call-webcast/) - MONTREAL, QUEBEC , January 25, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended October 31, 2022 on Monday January 30, 2023 after market close. The Company will host

## Pages

- [Home](https://valeopharma.com/) - Valeo Pharma provides healthcare professionals and patients with innovative therapeutic solutions focused on respiratory, specialty products, neurology and oncology.
- [Respiratory / Allergy](https://valeopharma.com/respiratory-products/) - Valeo’s portfolio of products is focused on four therapeutic areas: respiratory, specialty products, neurology and oncology. Products include Enerzair® breezhaler®, Atectura® breezhaler®, RedescaAmetop Gel 4%, M-Eslon, Onstryv, Yondelis
- [Relations avec les investisseurs](https://valeopharma.com/fr/relations-avec-les-investisseurs/) - [et_pb_section fb_built=”1″ custom_padding_last_edited=”on|phone” admin_label=”Section” _builder_version=”4.9.4″ _module_preset=”default” background_image=”https://valeopharma.com/wp-content/uploads/2021/06/investors-hero-2.svg” background_position=”bottom_right” vertical_offset=”-45px” custom_margin=”||80px||false|false” custom_margin_tablet=”” custom_margin_phone=”||0px||false|false” custom_margin_last_edited=”on|phone” custom_padding=”||57px|||” custom_padding_tablet=”” custom_padding_phone=”||0px||false|false” da_disable_devices=”off|off|off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row column_structure=”1_2,1_2″ make_equal=”on” _builder_version=”4.9.4″ _module_preset=”default” vertical_offset=”58px” custom_css_main_element=”overflow:visible!important;”][et_pb_column type=”1_2″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” header_text_color=”#1D0066″ header_6_text_color=”#9341FF” custom_margin=”||39px|||” animation_style=”fade” animation_duration=”1200ms” animation_delay=”350ms” text_text_color_tablet=”” text_text_color_phone=”#1D0066″ text_text_color_last_edited=”on|phone” header_text_color_tablet=”” header_text_color_phone=”#1D0066″ header_text_color_last_edited=”on|phone”] Relations avec les investisseurs Négociation des
- [Investor Relations](https://valeopharma.com/investor-relations/) - Valeo Pharma (CSE:VPH, OTCQB: VPHIF, FSE: VP2) is a Canadian pharmaceutical company focused on Respiratory, Neurology, Oncology and Specialty Products. Within these areas Valeo now has 8 marketed brands and 4 additional products contributing to significant growth for the coming year. For the latest highlights of Valeo’s innovations, read the latest Investor Deck.
- [Pour nous joindre](https://valeopharma.com/fr/pour-nous-joindre/) - [et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” custom_margin=”0px||||false|false” custom_padding=”0px||0px||false|false” da_disable_devices=”off|off|off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” background_image=”https://valeopharma.com/wp-content/uploads/2021/06/contact-hero.png” background_position=”bottom_left” width=”100%” max_width=”90%” max_width_tablet=”” max_width_phone=”100%” max_width_last_edited=”on|phone” module_alignment=”left” min_height=”60vh” min_height_tablet=”” min_height_phone=”20vh” min_height_last_edited=”on|phone” custom_margin=”0px|auto|35px|auto|false|false” custom_margin_tablet=”” custom_margin_phone=”0px|auto|0px|auto|false|false” custom_margin_last_edited=”on|phone” custom_padding=”0px||||false|false” animation_style=”flip” animation_duration=”1150ms”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][/et_pb_column][/et_pb_row][et_pb_row column_structure=”2_5,3_5″ _builder_version=”4.9.4″ _module_preset=”default” animation_style=”fade” animation_duration=”1200ms”][et_pb_column type=”2_5″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” header_font=”|800|||||||” header_font_size=”70px” header_letter_spacing=”-3px” custom_margin=”||63px|||” custom_padding=”||30px||false|false”
- [Contact](https://valeopharma.com/contact/) - If you have any questions, comments or requests related to Valeo Pharma products and services, please do not hesitate to contact us.
- [Rapports financiers](https://valeopharma.com/fr/rapports-financiers/) - [et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” background_image=”https://valeopharma.com/wp-content/uploads/2021/06/Business-development.svg” vertical_offset=”-143px” custom_margin=”||80px||false|false” custom_padding=”||57px|||” da_disable_devices=”off|off|off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row column_structure=”1_2,1_2″ make_equal=”on” _builder_version=”4.9.4″ _module_preset=”default” vertical_offset=”167px”][et_pb_column type=”1_2″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” custom_margin=”||41px|||” animation_style=”fade” animation_duration=”1200ms” animation_delay=”350ms”] Rapports financiers [/et_pb_text][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” header_3_text_color=”#1D0066″ header_3_font_size=”21px” width=”100%” custom_padding=”|||20px|false|false” animation_style=”fade” animation_delay=”300ms” hover_enabled=”0″ border_width_left=”5px” border_color_left=”rgba(112,112,112,0.18)” locked=”off” sticky_enabled=”0″] 2023 Q1 | Q2 | Q3 Rapport
- [Financial Reports](https://valeopharma.com/financial-reports/) - Valeo Pharma is committed to provide healthcare professionals and patients with innovative therapeutic solutions to improve quality of life.
- [FRENCH](https://valeopharma.com/fr/) - [et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” background_enable_image=”off” background_position=”center_right” min_height=”100vh” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” da_disable_devices=”off|off|off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row column_structure=”2_5,3_5″ use_custom_gutter=”on” gutter_width=”1″ make_equal=”on” disabled_on=”on|on|off” _builder_version=”4.9.4″ _module_preset=”default” width=”100%” max_width=”100%” module_alignment=”right” min_height=”72vh” custom_margin=”0px||0px|0px|false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_column type=”2_5″ _builder_version=”4.9.4″ _module_preset=”default” z_index=”99999999″ custom_padding=”10%|0%|10%|10%|true|false”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” header_font=”|300|||||||” header_font_size=”3.6vw” header_letter_spacing=”-1px” header_5_font=”noblis|500|||||||” header_5_text_color=”#01CB97″ header_5_font_size=”18px” header_5_letter_spacing=”2px” z_index=”500″ width=”107.8%” width_tablet=”” width_phone=”90%” width_last_edited=”on|phone” custom_margin=”||||false|false” custom_padding=”0px|0px|0px|0px|false|false” animation_style=”fade” animation_duration=”1150ms”
- [Produits de spécialité](https://valeopharma.com/fr/produits-de-specialite/) - [et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” background_image=”https://valeopharma.com/wp-content/uploads/2021/09/specialty-hero-web.jpg” min_height=”50vh” min_height_tablet=”” min_height_phone=”60vh” min_height_last_edited=”on|phone” da_disable_devices=”off|off|off” locked=”off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” background_color=”#e4f5f1″ custom_margin=”-200px||||false|false” custom_margin_tablet=”” custom_margin_phone=”-100px||||false|false” custom_margin_last_edited=”on|phone” custom_padding=”40px||40px||true|false” da_disable_devices=”off|off|off” border_radii=”off||300px||” border_radii_tablet=”” border_radii_phone=”off||100px||100px” border_radii_last_edited=”on|phone” locked=”off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” custom_padding=”0px||0px|||”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_blurb title=”Produits de spécialité” image=”https://valeopharma.com/wp-content/uploads/2021/06/hospital.svg” icon_placement=”left”
- [Specialty Products](https://valeopharma.com/specialty-products/) - Valeo’s portfolio of products is focused on four therapeutic areas: respiratory, specialty products, neurology and oncology. Products include Enerzair® breezhaler®, Atectura® breezhaler®, RedescaAmetop Gel 4%, M-Eslon, Onstryv, Yondelis
- [Webdiffusion et événements](https://valeopharma.com/fr/webdiffusion-et-evenements/) - [et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” background_image=”https://valeopharma.com/wp-content/uploads/2021/06/products-hero-2.svg” min_height=”40vh” min_height_tablet=”” min_height_phone=”20vh” min_height_last_edited=”on|phone” custom_padding=”||58px|||” da_disable_devices=”off|off|off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” positioning=”absolute” position_origin_a=”center_center”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” width=”650px” max_width=”100%” max_width_tablet=”” max_width_phone=”80%” max_width_last_edited=”on|phone” module_alignment=”center” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|phone”] Webdiffusion et Événements Nous espérons que vous serez des nôtres lors de nos conférences téléphoniques, webinaires et
- [Events](https://valeopharma.com/events/) - We hope you’ll join us for our regular conference calls, webinars and events. Dates and details will always be shared here:
- [Respiratoire / Allergie](https://valeopharma.com/fr/respiratoire/) - [et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” background_image=”https://valeopharma.com/wp-content/uploads/2022/04/valeo-breathe-web-scaled-2-1.jpg” background_position=”bottom_center” min_height=”50vh” min_height_tablet=”60vh” min_height_phone=”30vh” min_height_last_edited=”on|phone” da_disable_devices=”off|off|off” locked=”off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” background_color=”#e4f5f1″ custom_margin=”-200px||||false|false” custom_margin_tablet=”” custom_margin_phone=”-100px||||false|false” custom_margin_last_edited=”on|phone” custom_padding=”40px||40px||true|false” da_disable_devices=”off|off|off” border_radii=”off||300px||” border_radii_tablet=”” border_radii_phone=”off||100px||100px” border_radii_last_edited=”on|phone” locked=”off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” custom_padding=”0px||0px|||”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_blurb title=”Respiratoire / Allergie” image=”https://valeopharma.com/wp-content/uploads/2021/06/respiratory.svg”
- [Ophtalmologie](https://valeopharma.com/fr/ophtalmologie/) - Valeo’s portfolio of products is focused on four therapeutic areas: respiratory, specialty products, neurology and oncology. Products include Enerzair® breezhaler®, Atectura® breezhaler®, RedescaAmetop Gel 4%, M-Eslon, Onstryv, Yondelis
- [Ophthalmology](https://valeopharma.com/ophthalmology/) - Valeo’s portfolio of products is focused on four therapeutic areas: respiratory, specialty products, neurology and oncology. Products include Enerzair® breezhaler®, Atectura® breezhaler®, RedescaAmetop Gel 4%, M-Eslon, Onstryv, Yondelis
- [Partenariat](https://valeopharma.com/fr/partenariat/) - [et_pb_section fb_built=”1″ custom_padding_last_edited=”on|phone” _builder_version=”4.9.4″ _module_preset=”default” background_image=”https://valeopharma.com/wp-content/uploads/2021/06/Business-development.svg” background_position=”top_right” vertical_offset=”-143px” custom_margin=”||80px||false|false” custom_margin_tablet=”” custom_margin_phone=”||60px||false|false” custom_margin_last_edited=”on|phone” custom_padding=”||57px|||” custom_padding_tablet=”” custom_padding_phone=”||50px||false|false” da_disable_devices=”off|off|off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row column_structure=”1_2,1_2″ make_equal=”on” _builder_version=”4.9.4″ _module_preset=”default” vertical_offset=”167px”][et_pb_column type=”1_2″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” custom_margin=”||81px|||” custom_margin_tablet=”” custom_margin_phone=”||40px||false|false” custom_margin_last_edited=”on|phone” animation_style=”fade” animation_duration=”1200ms” animation_delay=”350ms” text_text_color_tablet=”” text_text_color_phone=”#FFFFFF” text_text_color_last_edited=”on|phone” header_text_color_tablet=”” header_text_color_phone=”#FFFFFF” header_text_color_last_edited=”on|phone”] Développement d’affaires “Notre objectif premier et la
- [Business Development](https://valeopharma.com/business-development/) - Valeo Pharma has built its business on a foundation of strong partnerships with International Pharmaceutical Companies. We look for partners with world class R&D and state of the art manufacturing facilities to complement our own internal capabilities.
- [A Props De Nous](https://valeopharma.com/fr/a-props-de-nous/) - [et_pb_section fb_built=”1″ custom_padding_last_edited=”on|phone” _builder_version=”4.9.4″ _module_preset=”default” custom_padding=”80px|3px|98px|||” custom_padding_tablet=”” custom_padding_phone=”50px|3px|50px||true|false” da_disable_devices=”off|off|off” locked=”off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row column_structure=”2_3,1_3″ make_equal=”on” _builder_version=”4.9.4″ _module_preset=”default” min_height=”284.8px” custom_margin=”||||false|false” custom_padding=”0px|0px|0px|0px|true|true”][et_pb_column type=”2_3″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” position_origin_a=”center_left” width=”72%” custom_margin=”||-100px||false|false” custom_padding=”||20px||false|false” custom_padding_tablet=”” custom_padding_phone=”||0px||false|false” custom_padding_last_edited=”on|phone” animation_style=”fade” animation_duration=”1300ms” hover_enabled=”0″ sticky_enabled=”0″] Les racines canadiennes de Valeo Enracinée dans l’industrie pharmaceutique spécialisée, Valeo fait
- [The Company](https://valeopharma.com/the-company/) - Rooted in specialty pharma, Valeo is growing Canadian healthcare by licensing and acquiring Canadian rights to commercial stage, innovative and proprietary drugs, with no development or clinical activities associated risks.
- [Newsroom](https://valeopharma.com/newsroom/) - Latest news releases, product updates and financials for Valeo Pharma (CSE:VPH)
- [Actualités et médias](https://valeopharma.com/fr/actualites-et-medias/) - [et_pb_section fb_built=”1″ admin_label=”Section” _builder_version=”4.9.4″ _module_preset=”default” background_image=”https://valeopharma.com/wp-content/uploads/2021/06/news-hero.svg” background_position=”bottom_center” custom_padding=”29px||11px|||” da_disable_devices=”off|off|off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” custom_padding=”64px||15px|||”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_text _builder_version=”4.9.4″ _module_preset=”default” custom_margin=”||11px|||” animation_style=”fade” animation_duration=”1250ms”] Actualités et médias [/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” custom_margin=”6px|auto||auto||” custom_padding=”19px|||||”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_blog posts_number=”1″ include_categories=”26″ excerpt_length=”170″ show_more=”on” show_author=”off” show_pagination=”off” _builder_version=”4.9.4″ _module_preset=”default” header_level=”h4″ header_font_size=”34px” header_line_height=”1.1em” body_font_size=”18px” meta_font=”|700||on|||||” meta_font_size=”13px” custom_margin=”6px|||||”
- [Products](https://valeopharma.com/our-products/) - Valeo’s portfolio of products is focused on four therapeutic areas: respiratory, specialty products, neurology and oncology. Products include Enerzair® breezhaler®, Atectura® breezhaler®, RedescaAmetop Gel 4%, M-Eslon, Onstryv, Yondelis
- [Portefeuille de Produits](https://valeopharma.com/fr/apercu-des-produits/) - [et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” background_color=”RGBA(0,0,0,0)” custom_padding=”0px||0px||false|false” da_disable_devices=”off|off|off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row column_structure=”1_2,1_2″ make_equal=”on” _builder_version=”4.9.4″ _module_preset=”default” background_enable_image=”off” width=”82%” width_tablet=”” width_phone=”100%” width_last_edited=”on|phone” max_width=”100%” module_alignment=”left” min_height=”70vh” custom_padding=”0px||0px||false|false”][et_pb_column type=”1_2″ _builder_version=”4.9.4″ _module_preset=”default” background_image=”https://valeopharma.com/wp-content/uploads/2021/08/valeo-breathe-web-scaled.jpg” custom_padding_tablet=”” custom_padding_phone=”150px||150px||true|false” custom_padding_last_edited=”on|phone” border_radii=”off|||450px|”][et_pb_code _builder_version=”4.9.4″ _module_preset=”default”] [/et_pb_code][/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.9.4″ _module_preset=”default” custom_padding=”8%|3%|8%|3%|true|true”][et_pb_text content_tablet=”” content_phone=” Aperçu des produits “Valeo Pharma se concentre sur l’apport de
- [Careers](https://valeopharma.com/careers/) - Valeo Pharma recruits and develops passionate and committed individuals with a thirst for knowledge, hunger for challenge and desire to be part of a winning team.
- [Carriéres](https://valeopharma.com/fr/carrieres/) - [et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” background_color=”#FFBD27″ use_background_color_gradient=”on” background_color_gradient_start=”#ffbd27″ background_color_gradient_end=”#ffffff” background_color_gradient_start_position=”53%” background_color_gradient_end_position=”53%” min_height=”50vh” da_disable_devices=”off|off|off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” min_height=”20vh” height=”20vh” custom_margin=”||||false|false” custom_padding=”0px||0px||false|false” animation_style=”fold” animation_duration=”1300ms” animation_intensity_fold=”31%”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default” background_image=”https://valeopharma.com/wp-content/uploads/2021/07/valeo-careers.jpg” background_position=”top_center” custom_padding=”20vh||20vh||false|false” border_radii=”off||90px||90px”][et_pb_code _builder_version=”4.9.4″ _module_preset=”default”] [/et_pb_code][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” custom_padding=”6px|||||” da_disable_devices=”off|off|off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default”][et_pb_column
- [Oncology](https://valeopharma.com/oncology-products/) - Valeo Pharma provides healthcare professionals and patients with innovative therapeutic solutions focused on respiratory, specialty products, neurology and oncology.
- [Neurodegenerative Diseases](https://valeopharma.com/neurodegenerative-diseases/) - Valeo Pharma provides healthcare professionals and patients with innovative therapeutic solutions focused on respiratory, specialty products, neurology and oncology.
- [Neurologie](https://valeopharma.com/fr/neurologie/) - [et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” background_image=”https://valeopharma.com/wp-content/uploads/2021/09/neurology-hero.jpg” min_height=”50vh” min_height_tablet=”60vh” min_height_phone=”30vh” min_height_last_edited=”on|phone” da_disable_devices=”off|off|off” locked=”off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” background_color=”#e4f5f1″ custom_margin=”-200px||||false|false” custom_margin_tablet=”” custom_margin_phone=”-100px||||false|false” custom_margin_last_edited=”on|phone” custom_padding=”40px||40px||true|false” da_disable_devices=”off|off|off” border_radii=”off||300px||” border_radii_tablet=”” border_radii_phone=”off||100px||100px” border_radii_last_edited=”on|phone” locked=”off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” custom_padding=”0px||0px|||”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_blurb title=”Neurologie” image=”https://valeopharma.com/wp-content/uploads/2021/06/nero.svg” icon_placement=”left” image_max_width=”93%” content_max_width=”100%”
- [Oncologie](https://valeopharma.com/fr/oncologie/) - [et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” background_image=”https://valeopharma.com/wp-content/uploads/2021/09/oncology-hero-web.jpg” min_height=”50vh” min_height_tablet=”” min_height_phone=”60vh” min_height_last_edited=”on|phone” da_disable_devices=”off|off|off” locked=”off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.4″ _module_preset=”default” background_color=”#e4f5f1″ custom_margin=”-200px||||false|false” custom_margin_tablet=”” custom_margin_phone=”-100px||||false|false” custom_margin_last_edited=”on|phone” custom_padding=”40px||40px||true|false” da_disable_devices=”off|off|off” border_radii=”off||300px||” border_radii_tablet=”” border_radii_phone=”off||100px||100px” border_radii_last_edited=”on|phone” locked=”off” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.9.4″ _module_preset=”default” custom_padding=”0px||0px|||”][et_pb_column type=”4_4″ _builder_version=”4.9.4″ _module_preset=”default”][et_pb_blurb title=”Oncologie” image=”https://valeopharma.com/wp-content/uploads/2021/06/oncology.svg” icon_placement=”left” image_max_width=”85%” content_max_width=”100%”
- [ERP Subscription](https://valeopharma.com/erp-subscription/) - Valeo Pharma provides healthcare professionals and patients with innovative therapeutic solutions focused on respiratory, specialty products, neurology and oncology.
- [Press Release Uploader](https://valeopharma.com/press-release-uploader/) - [sp-client-document-manager]

## Categories

- [Uncategorized](https://valeopharma.com/category/uncategorized/)
- [News Release](https://valeopharma.com/category/news-release/)
- [Communiqué de presse](https://valeopharma.com/category/communique-de-presse/)